Early Success of a New COVID-19 Vaccine in the UK

Background on COVID-19

Since the onset of the pandemic on December 31, 2019, nearly 14.5 million COVID-19 cases have been reported globally, resulting in over 600,000 deaths. In the Americas alone, the death toll exceeds 311,000.

Vaccine Development Efforts

Scientists around the world have been working diligently to create an effective vaccine for COVID-19. Currently, at least ten vaccine candidates are undergoing clinical trials. Healthcare providers are seeking a vaccine that can be administered in one or two doses, effectively protect vulnerable populations such as the elderly and immunocompromised, maintain efficacy for at least six months, and reduce virus transmission.

Preliminary Study Results

One promising vaccine being tested in the UK has shown early positive results in terms of safety and efficacy. Preliminary findings were published in the medical journal The Lancet.

Vaccine Mechanism

This COVID-19 vaccine utilizes a modified common cold virus, specifically one that typically infects chimpanzees but is harmless to humans. The vaccine is engineered to deliver the genetic code for the COVID-19 spike protein, which is essential for the virus’s ability to infect cells. Once administered, the patient’s cells produce the spike protein, training the immune system to recognize and combat the virus.

Professor Andrew Pollard from the University of Oxford, a lead author of the study, explained that the vaccine aims to stimulate both antibody and T-cell responses from the immune system. This dual approach is designed to enable the immune system to target the virus while it circulates in the body and also to attack infected cells.

Study Design and Patient Response

The ongoing study involves 1,077 healthy participants aged 18 to 55, with data collected between April 23 and May 21, 2020. Participants were split into two groups: one receiving a high dose of the COVID-19 vaccine and the other receiving a meningitis vaccine. The participants were divided into four groups for different follow-up protocols.

Group 1 underwent intensive monitoring to ensure vaccine safety and to evaluate antibody and T-cell responses. Group 2 provided additional blood samples for testing, while Group 3 received a second dose of the COVID-19 vaccine 28 days later. Group 4 had blood serum samples taken to assess the vaccine’s antibody response.

To evaluate the effectiveness of over-the-counter pain relief, ten percent of participants took acetaminophen before and after receiving the vaccine. The most frequently reported side effects included fatigue and headache, but those who took acetaminophen experienced fewer adverse effects. Other common side effects included pain at the injection site, muscle aches, chills, and elevated temperature.

Immune Response Findings

Participants who received the COVID-19 vaccine exhibited strong antibody and T-cell responses. The T-cell response peaked two weeks post-vaccination, while the antibody response peaked four weeks after vaccination and was further enhanced by the second dose.

Future Outlook

These positive results indicate promising prospects for phase three trials, where the COVID-19 vaccine will be evaluated in a larger population.

References

Folegatti, P., Ewer, K., Aley, P., Angus, B., Becker, S., & Belij-Rammerstorfer, S. et al. (2020). Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomized controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)31604-4

COVID-19 situation update worldwide, as of 20 July 2020. European Centre for Disease Prevention and Control. (2020). Retrieved 20 July 2020, from https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases.

Vaccines and treatment of COVID-19. European Centre for Disease Prevention and Control. (2020). Retrieved 20 July 2020, from https://www.ecdc.europa.eu/en/covid-19/latest-evidence/vaccines-and-treatment.

Benedette Cuffari, M. (2020). What are Spike Proteins?. News-Medical.net. Retrieved 20 July 2020, from https://www.news-medical.net/health/What-are-Spike-Proteins.aspx.